Registration system for nephrotic syndrome patients in China

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study aims to create a comprehensive database for nephrotic syndrome (NS) patients in China, capturing a wide range of demographic, clinical, and pathological data. All patients with NS, regardless of the underlying cause, will be registered and followed up to monitor treatment responses and changes in renal function over time. The study will analyze various outcomes, including renal survival, patient survival, and complications such as infections and acute kidney injury, using the collected data. This initiative seeks to enhance understanding of nephrotic syndrome and improve patient management.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Nephrotic syndrome patients regardless of the primary causes

Exclusion Criteria:

* No

Where it's running

• The 1st Affiliated Hospital, Sun Yet-sen University
  Guangzhou, Guangdong, China Recruiting

Study contacts

• Study coordinator: Xueqing Yu, M.D. & Ph.D
• Email: yuxq@mail.sysu.edu.cn

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Smartphone app to help follow the 2024 KDIGO chronic kidney disease guidelines

  This project will test whether a smartphone app helps young adults (ages 16–29) with chronic kidney disease follow the 2024 KDIGO guideline recommendations.

  Recruiting at 2 sites St. James's Hospital, Ireland · Dublin and 1 other locations · NCT07561957

• SGLT2 inhibitors added to standard care in adult primary nephrotic syndrome

  This trial tests whether adding dapagliflozin or empagliflozin to standard treatment helps reduce protein in urine for adults with primary nephrotic syndrome.

  Recruiting Phase 2/3 Mansoura University · Al Mansurah, Dakahlia Governorate · NCT07214818

• Atacicept for multiple autoimmune glomerular diseases

  This will test whether weekly injections of atacicept can lower protein in the urine and help preserve kidney function in people aged 10 and older with IgA nephropathy, primary membranous nephropathy, or nephrotic syndromes such as MCD and FSGS.

  Recruiting Phase 2 Vera Therapeutics, Inc. · Brisbane, California · NCT06983028

• Multitarget approach for primary podocytopathies

  This project will test whether a lab cell culture can find a factor in the blood that causes proteinuria in people with primary podocytopathies and whether a combined therapy can block that factor in vitro.

  Recruiting at 2 sites Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico · Milan and 1 other locations · NCT06718894

• Follow-up on Rituximab treatment for children's nephrotic syndrome

  This study looks at how well rituximab works and its safety for children with hard-to-treat nephrotic syndrome by reviewing their past treatment data.

  Recruiting The First Affiliated Hospital of Xiamen University · Xiamen, Fujian · NCT06530004

• Investigating the role of a protein in kidney damage related to nephrotic syndrome

  This study is trying to see if a protein called PCSK9 is linked to kidney damage and high cholesterol in people with nephrotic syndrome.

  Recruiting Kolding Sygehus · Kolding · NCT06373913

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.